Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086196 · ClinicalTrials.gov registry record
A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 350
- Enrollment target
NCT07086196 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 350 participants.
The verdict
NCT07086196 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
Study Summary
The main aim of this study was to describe the profile of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) patients who received first-line (1L) current treatment options with ribociclib in the United States (US) clinical practice. This study used administrative claims data. De-identified patient-level data of adult patients with HR+/HER2- mBC who initiated 1L treatment with a cyclin dependant kinase 4/6 inhibitor (CDK4/6i) i.e., ribociclib from the Komodo Health Solutions Research Database (KRD; data from 1 January 2016 to 30 June 2023) was used. Data included medical and pharmacy claims for insured patients, which had already been collected (i.e., secondary use of data).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2024-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07086196
The ClinicalTrials.gov registry entry for NCT07086196 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07086196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07086196 about?
NCT07086196 is a clinical study titled "A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer". The main aim of this study was to describe the profile of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) patients who received first-line (1L) current treatment options with ribociclib in the United States (US) clinical practice...
What is the current status of trial NCT07086196?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2024-05-30. Estimated completion is 2024-08-30.
Who is sponsoring clinical trial NCT07086196?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.